EEG Dynamics in Lennox-Gastaut Syndrome Patients Undergoing Fenfluramine Treatment

Conditions

• Lennox Gastaut Syndrome (LGS)

Eligibility Criteria

Sex

ALL

Age

2 Years - 35 Years

Healthy Volunteers

Not accepted

Interventions

• fenfluramine HCl — DRUG
  Patients who receive fenfluramine will be enrolled in this non-interventional study.

Study Details

This study plans to learn if certain markers found during electroencephalogram (EEG) analysis could predict fenfluramine responsiveness to give clinicians greater insight into the effectiveness of fenfluramine in people with Lennox Gastaut Syndrome (LGS).

Key Dates

Start date

Apr 30, 2026

Status verified

May 2026

Primary completion

Dec 31, 2027

Completion

Apr 30, 2028

Study Design

Enrollment

20 participants (estimated)

Primary Outcome Measure

Number of participants who have concordance between electroencephalogram (EEG) changes and clinical responsiveness in patients diagnosed with Lennox-Gastaut Syndrome (LGS) undergoing treatment with fenfluramine after 6 months. [ Time Frame: from EEG prior to fenfluarmine initiation to follow up EEG 6 months after ]

Locations (1)

Find similar trials in Chicago, IL